Purdue Pharma LP’s initiative to diversify includes business deals on multiple fronts, including in its core area of pain but also in new “innovative” areas and through commercialization deals with ex-US partners, CEO Mark Timney said in a recent interview.
The chief executive has set deal-making as a top priority for Purdue since taking over the helm of the private specialty pharma in early 2014. The strategy is a key...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?